California-based Coherus BioSciences, Inc. is taking the biosimilar and immuno-oncology market in the United States by storm. Specializing in the space, the biopharmaceutical company has a range of products that are interchangeably used with known drugs. This includes UDENYCA, a long-acting granulocyte-colony stimulating factor that is comparable to Neulasta, and CIMERLI, a product used for the treatment of macular conditions like macular edema and diabetic retinopathy. Coherus BioSciences, Inc. also offers YUSIMRY, a biosimilar to Humira for inflammatory diseases. The company has tied up with some big names in the industry, such as Selexis SA, Pfizer, Inc., and AbbVie, Inc., to name a few. Formerly known as BioGenerics, Inc., the firm changed its name to Coherus BioSciences, Inc. in 2012.
Coherus BioSciences's ticker is CHRS
The company's shares trade on the NASDAQ stock exchange
They are based in Redwood City, California
There are 51-200 employees working at Coherus BioSciences
It is coherus.com/about-coherus
Coherus BioSciences is in the Healthcare sector
Coherus BioSciences is in the Biotechnology industry
The following five companies are Coherus BioSciences's industry peers: